6 reports of this reaction
2.5% of all NYSTATIN AND TRIAMCINOLONE ACETONIDE reports
#5 most reported adverse reaction
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION is the #5 most commonly reported adverse reaction for NYSTATIN AND TRIAMCINOLONE ACETONIDE, manufactured by Alembic Pharmaceuticals Inc.. There are 6 FDA adverse event reports linking NYSTATIN AND TRIAMCINOLONE ACETONIDE to DRUG INEFFECTIVE FOR UNAPPROVED INDICATION. This represents approximately 2.5% of all 237 adverse event reports for this drug.
Patients taking NYSTATIN AND TRIAMCINOLONE ACETONIDE who experience drug ineffective for unapproved indication should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION is a less commonly reported adverse event for NYSTATIN AND TRIAMCINOLONE ACETONIDE, but still significant enough to appear in the safety profile.
In addition to drug ineffective for unapproved indication, the following adverse reactions have been reported for NYSTATIN AND TRIAMCINOLONE ACETONIDE:
The following drugs have also been linked to drug ineffective for unapproved indication in FDA adverse event reports:
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION has been reported as an adverse event in 6 FDA reports for NYSTATIN AND TRIAMCINOLONE ACETONIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION accounts for approximately 2.5% of all adverse event reports for NYSTATIN AND TRIAMCINOLONE ACETONIDE, making it a notable side effect.
If you experience drug ineffective for unapproved indication while taking NYSTATIN AND TRIAMCINOLONE ACETONIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.